Using its chemistry and chemoinformatics platforms, Priaxon AG has discovered small molecules that inhibit the interaction between MDM2 and p53, thereby hindering tumor growth. The company believes its MDM2/p53 inhibitors could provide greater efficacy and will be more easily optimized than MDM2 antagonists already in the clinic against cancer.

Last month, Boehringer Ingelheim GmbH licensed rights to develop and commercialize the MDM2 program for cancer.